The Epidermal Growth Factor Receptor (EGFR) and broader receptor tyrosine kinase (RTK) growth factor signaling pathway represents a compelling but challenging therapeutic target for Parkinson's disease. Unlike oncology where EGFR inhibition is the goal, neurodegeneration requires activation of EGFR signaling to promote dopaminergic neuron survival, mitochondrial protection, and neurogenesis. The field is nascent — no EGFR-specific therapy has reached clinical trials for PD — but growing evidence supports the approach[1].
EGFR is widely expressed in dopaminergic neurons of the substantia nigra pars compacta, where it regulates critical neuroprotective functions[2]:
The primary challenge is blood-brain barrier penetration — native EGF does not cross the BBB[8]. Current strategies focus on brain-penetrant small molecules, modified EGF peptides, gene therapy delivery, and RTK agonists that activate overlapping pathways[9].
This category catalogs companies developing:
The EGFR/RTK therapy field for Parkinson's disease is in early stages:
| Category | Stage | Companies | Notes |
|---|---|---|---|
| Direct EGFR agonists | Preclinical | Research only | BBB challenge significant |
| HGF/MET agonists | Phase 2 (AD), PD planned | Athira Pharma | Closest to clinic |
| FGF-based therapies | Preclinical/Phase 1 | Trefoil Therapeutics | Broader RTK category |
| EGFR gene therapy | Preclinical | Academic/research | AAV delivery approaches |
| EGFR kinase modulators | Discovery | Various | Positive modulators, not inhibitors |
| BBB-penetrant EGF | Research | Academic | Peptide engineering |
Focus: HGF/MET receptor activator — closely related RTK pathway
Drug: Fosgonimeton (ATH-1017)
Mechanism: Athira's fosgonimeton activates the MET receptor (hepatocyte growth factor receptor), a receptor tyrosine kinase in the same ErbB superfamily as EGFR. MET signaling shares downstream pathways with EGFR (PI3K/Akt, MAPK/ERK), providing similar neuroprotective effects including neuronal survival, synaptic plasticity, and mitochondrial support. The HGF/MET system is naturally involved in brain repair and is downregulated in neurodegenerative disease.
Pipeline:
| Drug | Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| Fosgonimeton (ATH-1017) | HGF/MET agonist | Alzheimer's disease | Phase 2/3 | ACT-AD study recruiting |
| Fosgonimeton | HGF/MET agonist | Parkinson's disease dementia | Phase 2 | Planning |
| ATH-1020 | HGF/MET agonist | Alzheimer's disease | Preclinical | Research |
| ATH-2205 | HGF/MET agonist | Neurodegeneration | Discovery | Research |
Clinical Development:
Advantages: Oral administration, favorable safety profile, disease-modifying mechanism through neuroprotection and repair.
Related Pages:
Focus: Engineered neurotrophic factors targeting RTK signaling
Drug: TF-202 (PD preclinical)
Mechanism: Trefoil's TF-202 is an engineered neurotrophic factor designed to support survival of dopaminergic neurons through receptor tyrosine kinase activation. The company applies protein engineering to create factors with improved pharmacological properties (half-life, brain penetration, stability) compared to native proteins.
Pipeline:
| Drug | Mechanism | Indication | Stage | Status |
|---|---|---|---|---|
| TF-201 | Synaptic growth factor (RTK agonist) | Alzheimer's disease | Phase 1 | Recruiting |
| TF-202 | Neuroprotective factor (RTK agonist) | Parkinson's disease | Preclinical | IND-enabling |
TF-202 for PD:
Company Details:
Related Pages:
Multiple academic groups and early-stage companies are developing EGFR-targeted approaches for PD:
Modified EGF peptides designed to cross the blood-brain barrier:
Heparin-binding EGF-like growth factor derivatives:
Drug discovery efforts targeting positive allosteric modulators of EGFR:
Neuregulin-1 signals through ErbB3/ErbB4 receptors, closely related to EGFR:
The following companies have growth factor or RTK-adjacent programs for PD:
| Approach | Description | Status | Companies |
|---|---|---|---|
| EGF peptide fragments | BBB-penetrant EGF derivatives | Preclinical | Research only |
| HB-EGF mimetics | Modified heparin-binding EGF | Research | Academic |
| EGFR kinase agonists | Small molecule activators | Discovery | Various |
| Approach | Description | Status | Companies |
|---|---|---|---|
| HGF/MET agonists | HGF/MET signaling (shares EGFR pathways) | Phase 2 | Athira Pharma |
| FGF/FGFR modulators | Fibroblast growth factor signaling | Phase 1 | Trefoil |
| NRG1/ErbB4 | Neuregulin-1 ErbB receptor activation | Preclinical | Research |
| VEGF/VEGFR | Vascular endothelial growth factor | Preclinical | Research |
| Approach | Description | Status | Companies |
|---|---|---|---|
| AAV-EGF | AAV-mediated EGF expression | Preclinical | Academic |
| AAV-HGF | AAV-mediated HGF expression | Preclinical | Various |
| Regulatable expression | Small molecule-controlled growth factor levels | Research | Academic |
| Combination | Rationale | Status |
|---|---|---|
| EGFR + LRRK2 inhibitors | Complementary neuroprotection | Preclinical |
| EGFR + GBA modulators | Combined endolysosomal support | Preclinical |
| EGFR + DBS | Adjunctive neuroprotection near electrode | Research |
| Company | Drug/Program | Mechanism | Indication | Stage |
|---|---|---|---|---|
| Athira Pharma | Fosgonimeton (ATH-1017) | HGF/MET agonist | Alzheimer's disease | Phase 2/3 |
| Athira Pharma | Fosgonimeton | HGF/MET agonist | PD dementia | Phase 2 (planning) |
| Trefoil Therapeutics | TF-201 | Synaptic growth factor (RTK) | Alzheimer's disease | Phase 1 |
| Trefoil Therapeutics | TF-202 | Neuroprotective factor (RTK) | Parkinson's disease | Preclinical |
| Various | EGF peptide fragments | Direct EGFR agonist | PD | Preclinical |
| Various | HB-EGF mimetics | EGFR/ErbB agonist | PD | Research |
| Various | EGFR small molecule activators | EGFR kinase activation | PD | Discovery |
| Academic | AAV-EGF | Gene therapy | PD | Preclinical |
EGFR signaling provides multiple neuroprotective mechanisms directly relevant to PD pathophysiology:
EGFR intersects with major PD genetic risk factors:
EGFR expression and signaling decrease in the substantia nigra with normal aging, potentially contributing to increased vulnerability to neurodegeneration. This suggests EGFR support could be particularly beneficial in aging populations.
Native EGF (7 kDa) does not efficiently cross the BBB.
Current Solutions:
Chronic EGFR activation could theoretically promote tumor growth.
Current Solutions:
The optimal level of EGFR activation is unclear.
Current Solutions:
EGFR activation protects dopaminergic neurons in PD models. 2022. ↩︎
EGFR maintains mitochondrial function in dopaminergic neurons. 2024. ↩︎
EGFR-mediated autophagy in alpha-synuclein clearance. 2022. ↩︎
EGFR promotes neurogenesis in the subventricular zone. 2021. ↩︎
LRRK2 regulates EGFR trafficking in Parkinson's disease. 2023. ↩︎
EGFR-PINK1 cross-talk in mitochondrial quality control. 2023. ↩︎
BBB-penetrant EGFR modulators for neurodegenerative disease. 2024. ↩︎
Small molecule EGFR modulators for neurological disease. 2023. ↩︎